# US 2003/0225256 A1 · Antisense modulation of pctaire protein kinase 2 expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225256 A1
- Document ID: US20030225256A1
- Status: Published application
- Kind: A1
- Application number: 10/160,787
- Filed: 2002-05-31
- Published: 2003-12-04
- Earliest claimed: 2002-05-31
- Assignees: Isis Pharmaceuticals, Inc.
- Inventors: Andrew T. Watt
- Web page: https://patentgrep.com/patent/US20030225256A1

## CPC

- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- Y02P 20/582: Recycling of unreacted starting or intermediate materials
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of PCTAIRE protein kinase 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PCTAIRE protein kinase 2. Methods of using these compounds for modulation of PCTAIRE protein kinase 2 expression and for treatment of diseases associated with expression of PCTAIRE protein kinase 2 are provided.

## Claims

### Claim 1

An antisense oligonucleotide 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding PCTAIRE protein kinase 2, wherein said antisense oligonucleotide specifically hybridizes with said nucleic acid molecule encoding PCTAIRE protein kinase 2 and has a sequence comprising SEQ ID NO: 14, 15, 16, 18, 19, 20, 21, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 49, 50, 54, 55, 57, 58, 59, 60, 61, 62, 63, 65, 66, 68, 69, 70, 71, 75, 76, 78, 79, 80, 84, 85, 86, 89 or 91.

### Claim 2 (depends on 1)

The antisense oligonucleotide of claim 1 which comprises at least one modified internucleoside linkage.

### Claim 3 (depends on 2)

The antisense oligonucleotide of claim 2 wherein the modified internucleoside linkage is a phosphorothioate linkage.

### Claim 4 (depends on 1)

The antisense oligonucleotide of claim 1 which comprises at least one modified sugar moiety.

### Claim 5 (depends on 4)

The antisense oligonucleotide of claim 4 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.

### Claim 6 (depends on 1)

The antisense oligonucleotide of claim 1 which comprises at least one modified nucleobase.

### Claim 7 (depends on 6)

The antisense oligonucleotide of claim 6 wherein the modified nucleobase is a 5-methylcytosine.

### Claim 8 (depends on 1)

The antisense oligonucleotide of claim 1 which is a chimeric oligonucleotide.

### Claim 9

A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding PCTAIRE protein kinase 2.

### Claim 10 (depends on 1)

A composition comprising the antisense oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 11 (depends on 10)

The composition of claim 10 further comprising a colloidal dispersion system.
